Skip to content

Ashwagandhaadi Taila nasya in Sleeplessness due to stress

Randomized Controlled Clinical Study Of Ashwagandhaadi Taila Nasya In The Management Of Anidra W.S.R. To Stress Induced Insomnia - RCCSATNMAWSRSII

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/04/018424
Enrollment
40
Registered
2019-04-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G470- Insomnia

Interventions

Intervention1: GROUP A- Ashwagandhaadi Taila Nasya: In this group, 20 patients will be administered with 3 sittings of nasya procedure. Each sitting includes 7 days with 3 days interval in between

Sponsors

Uttarkhand Ayurved UniversityHarrawala Dehradun
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient fulfilling DSM-V criteria for insomnia. Patient fit for NASYA procedure. Patient not hypersensitive to any benzodiazepine.

Exclusion criteria

Exclusion criteria: Patient having chronic illness(diabetes mellitus,hypertension etc.). Patient having any severe psychiatric disorder( schizophrenia,OCD). Patient having allergy with oil application specially through nasal route.

Design outcomes

Primary

MeasureTime frame
To assess the effect of nasya karma, subjectively and objectively the following classical criteria will be taken.Only objective parameters will be employed for the assessment of the impact of treatment procedures in the respective group. Complete remission : 100% relief Markedly improvement : 76-99% relief Moderately improvement: 51%-75% relief Mild Improvement : 26%-50% relief Unchanged : 25% relief Timepoint: To assess the effect of nasya karma, subjectively and objectively the following classical criteria will be taken.Only objective parameters will be employed for the assessment of the impact of treatment procedures in the respective group. Complete remission : 100% relief Markedly improvement : 76-99% relief Moderately improvement: 51%-75% relief Mild Improvement : 26%-50% relief Unchanged : 25% relief

Secondary

MeasureTime frame
Exacerbation of signs and symptomsTimepoint: 1 month

Countries

India

Contacts

Public ContactDr Alok Kumar Srivastava

Rishikul Campus,UAU, Haridwar

virgo.alok@gmail.com9045087121

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026